Skape Bio

Skape Bio is a biotechnology company harnessing Nobel Prize winning AI-powered protein design and synthetic biology to generate novel functional de novo designed modulators of integral membrane proteins. Our cutting-edge computational platform integrates deep evolutionary insights with advanced protein design methodologies tailored specifically for integral membrane proteins, generating molecules with exceptional developability and function. Our proprietary experimental platform enables high-throughput screening directly in human cells, bypassing the need for target solubilization and unlocking previously inaccessible GPCRs. This approach has demonstrated broad applicability across GPCR families, successfully delivering novel agonists and antagonists. Through de novo design, minibinders achieve precise control over target binding and possess biophysical properties that enable superior pharmacology, such as gut stability, potency, and selectivity, while offering a simpler manufacturing process compared to traditional antibodies. Skape Bio’s in-cell screening platform evaluates tens of thousands of designs in their natural cellular context, accelerating target-directed discovery and optimization for first- and best-in-class indications in oncology, inflammation, metabolic disease, and neurology. Our robust platform infrastructure also supports future active learning for improved AI-driven binder design. In addition to its in-house discovery programs, Skape Bio actively seeks partnerships with leading pharmaceutical companies to co-develop novel therapeutics and unique tool compounds. Skape Bio is headquartered in Copenhagen, Denmark, a spinout from the three-year “Modulate” collaboration between the BioInnovation Institute and the University of Washington’s Institute for Protein Design (IPD), founded and led by David Baker, recipient of the 2024 Nobel Prize in Chemistry.